Specialty Minerals Inc

Specialty Minerals is a subsidiary of Minerals Technologies, a resource- and technology-based organization that develops and produces performance-enhancing minerals, mineral-based and synthetic mineral products for the paper, steel, polymer, health care and other manufacturing industries on a worldwide basis. Its research teams are headquartered in Pennsylvania where more than 140 scientists, engineers and technicians investigate new technologies, products and applications. Many of these scientists hold doctoral degrees in inorganic, organic and colloid chemistry; chemical engineering; paper science; and fine particle technology. Specialty Minerals is a leading worldwide producer and supplier of precipitated calcium carbonate. SMI also mines and processes high-quality lime and limestone and pure talc for use in building products, paints, coatings, ceramics, polymers and automotive catalytic converters. Specialty Minerals has a location in Easton, Pa.

Specialty Minerals Inc, based in Bethlehem, PA, is a company that specializes in the production and distribution of minerals for various industrial applications. With a focus on quality and innovation, Specialty Minerals Inc serves a diverse range of industries, providing essential mineral solutions to meet their specific needs. Generated from their business information

Celldex Therapeutics is a biopharmaceutical company that applies its Immunotherapy Platform to treat various diseases. Its immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Celldex Therapeutics technology platform uses human monoclonal antibodies administered directly to patients to target dendritic cells and macrophages that are key cells in the immune system. Its APC Targeting Technology delivers an antigen that results in more efficient processing than a nontargeted antigen. The company develops various therapeutic human monoclonal antibody products. Its lead programs are for oncology targets. Celldex Therapeutics has two clinical programs under clinical evaluation for the therapy of cancer.